Abstract：Objective To explore the clinical efficacy and safety of Batroxobin combined with Agatroban in the treatment of acute ischemic stroke, so as to provide references for clinicians to choose rational drug regimens. Methods A total of 80 patients with acute ischemic stroke admitted to Liaoyang Central Hospital from April 2018 to July 2019 were selected as the study subjects. According to the random number table method, the subjects were divided into the experimental group and the control group, 40 cases in each group. The control group was given routine treatment, and the experimental group was given the combination of Batroxobin and Agatroban based on the control group. The total effective rate of clinical treatment, National Institute of Health stroke scale (NIHSS) score and incidence of adverse reactions were compared between the two groups. Results The total clinical effective rate of the experimental group(92.50%) was higher than that of the control group (75.00%), the difference was statistically significant (P＜0.05). The NIHSS scores of the patients in the two groups after treatment were lower than those before treatment, and the NIHSS score of the experimental group was lower than that of the control group, the differences were statistically significant(P＜0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P＞0.05).Conclusion In the treatment of patients with acute ischemic stroke, the combination of Batroxobin and Agatroban has ideal clinical effect, and can effectively improve the neurological deficit without increasing adverse reactions, which is worthy of recommendation.
张靖欣. 巴曲酶与阿加曲班联合用药方案治疗急性缺血性脑卒中的临床效果及安全性评价[J]. 中国当代医药, 2020, 27(7): 69-71.
ZHANG Jing-xin. Clinical efficacy and safety evaluation of Batroxobin combined with Agatroban in the treatment of acute ischemic stroke. 中国当代医药, 2020, 27(7): 69-71.
京公网安备 11010502046607号